Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T60076 |
Oritinib
SH-1028 |
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Oritinib (SH-1028) 是一种 EGFR 抑制剂,对 EGFR (wt)、EGFR (L858R)、EGFR (L861Q)、EGFR (L858R/T790M)、EGFR (d746-750) 的 IC50 分别为 18、0.7、4、0.1、1.4 和 0.89 nM , EGFR (d746-750/T790M), 分别。奥瑞替尼可用于治疗非小细胞肺癌的研究。 | |||
T39670 |
Oritinib mesylate
SH-1028 mesylate,Oritinib mesylate |
||
Oritinib mesylate (SH-1028) is a highly selective, orally active, pyrimidine-based irreversible inhibitor of epidermal growth factor receptor (EGFR) with a low half maximal inhibitory concentration (IC50) of 18 nM. It demonstrates potent efficacy against both EGFR-sensitive and resistant (T790M) mutations. Furthermore, Oritinib mesylate effectively suppresses the proliferation of tumor cells harboring EGFR mutations, regardless of their sensitivity or resistance. |